The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Bristol-Myers Squibb; MSD Oncology
Research Funding - MSD Oncology (Inst); Pierre Fabre (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Roche/Genentech; Roche/Genentech
 
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma.
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Merck; Pierre Fabre
Consulting or Advisory Role - Aduro Biotech; Amgen; Array BioPharma; Bristol-Myers Squibb; GlaxoSmithKline UK Ltd.; Hexal; MERCK; Novartis; OncoSec; Pierre Fabre; Roche
 
Jacob Schachter
Honoraria - Bristol-Myers Squibb; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; MSD
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Ana Arance
No Relationships to Disclose
 
Jean-Jacques Grob
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck KGaA; MSD Oncology; Novartis; Pierre Fabre; Roche/Genentech; Sun Pharma
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre
 
Laurent Mortier
No Relationships to Disclose
 
Adil Daud
Stock and Other Ownership Interests - TRex Bio
Consulting or Advisory Role - Bristol-Myers Squibb; Incyte; Merck; Novartis; Pfizer; Roche/Genentech; Xenocor
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals; Genentech; Incyte; Merck; Novartis; OncoSec
Patents, Royalties, Other Intellectual Property - OncoSec Inc; Texas Health Presbyterian Hospital; University of California, San Francisco
 
Matteo S. Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; IDEAYA Biosciences; MSD; Novartis; Pierre Fabre; Roche
 
Antoni Ribas
Stock and Other Ownership Interests - Advaxis; Arcus Biosciences; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; ImaginAb; Lutris; Merus; PACT Pharma; Rgenix; Tango Therapeutics
Honoraria - Amgen; Chugai/Roche; Genentech/Roche; Merck Sharp & Dohme; Novartis; Sanofi
Consulting or Advisory Role - Amgen; Chugai Pharma; Merck; Novartis; Sanofi
Research Funding - Agilent (Inst); Bristol-Myers Squibb (Inst)
 
Catriona M. McNeil
Research Funding - MSD Oncology (Inst)
 
Michal Lotem
Consulting or Advisory Role - Merck
 
James M. G. Larkin
Honoraria - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra ; Vitaccess
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra ; Vitaccess
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Merck Serono; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
 
Paul Lorigan
Honoraria - Amgen; Bristol-Myers Squibb; Merck; MSD; NeraCare GmbH; Novartis; Oncology Education; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Bart Neyns
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pfizer/EMD Serono; Roche; Sanofi
Speakers' Bureau - Novartis
Research Funding - Merck KGaA (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
 
Christian U. Blank
Stock and Other Ownership Interests - Forty Seven; Neon Therapeutics; Uniti Cars
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Third Rock Ventures
Research Funding - Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Teresa M. Petrella
Honoraria - Abbvie (I); Astellas Pharma (I); Bayer (I); Bristol-Myers Squibb; Genzyme; Incyte; Janssen (I); Merck; Novartis; Sanofi (I)
Consulting or Advisory Role - Abbvie (I); Astellas Pharma (I); Bayer (I); Bristol-Myers Squibb; Genzyme; InCyte; Janssen (I); Merck; Novartis
Research Funding - Novartis Canada Pharmaceuticals Inc; Roche Canada
 
Omid Hamid
Honoraria - Array BioPharma; Bristol-Myers Squibb; Novartis; Sanofi/Regeneron
Consulting or Advisory Role - Aduro Biotech; Akeso Biopharma; Amgen; Array BioPharma; BeiGene; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Immunocore; Incyte; Janssen; Merck; NextCure; Novartis; Regeneron; Roche; Sanofi; Seagen; Tempus; Zelluna
Speakers' Bureau - Array BioPharma; Bristol-Myers Squibb; Novartis; Sanofi/Regeneron
Research Funding - Aduro Biotech (Inst); Akeso Biopharma (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Torque (Inst); Zelluna (Inst)
 
Erin Jensen
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Clemens Krepler
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Scott J. Diede
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Caroline Robert
Consulting or Advisory Role - Amgen; Biothera; Bristol-Myers Squibb; CureVac; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi